Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Evidence-graded peptide references, protocol summaries, and regulatory tracking — the same independent, source-cited material we publish, organized for clinical use.
PeptideWellness is an independent editorial publication. We don't accept payment from manufacturers, pharmacies, or clinics for coverage or placement, and nothing here is medical advice — clinical decisions stay with the licensed prescriber.
Every peptide we cover has a source-cited reference page — mechanism, the human evidence (and where it runs out), dosing as reported in the literature, safety, and regulatory status. The sections below organize that material for clinical reference, alongside the compounding and regulatory intelligence prescribers ask about most.
Source-cited pages on each peptide — mechanism, evidence tier, dosing, safety, legal status.
Open the library →SourcingHow to evaluate accredited 503A/503B compounders, side by side.
Compare pharmacies →Regulatory503A/503B changes and compounding policy, with dates.
See updates →Standardized, prescriber-facing protocol packs.
Coming soonIndependent field reports — in production, not yet available.
See what's coming →PrimerRx pathways, DEA scheduling, telehealth, and insurance.
Read the primer →The pages prescribers reach for most, in one place: